Le Lézard
Classified in: Health
Subjects: OFR, PVP

Select Medical Corporation Closes Private Placement of $675 Million of 6.250% Senior Notes due 2026


MECHANICSBURG, Pa., Dec. 10, 2019 /PRNewswire/ -- Select Medical Holdings Corporation ("Holdings") (NYSE: SEM), today announced that Select Medical Corporation ("Select") has completed its private placement of $675 million aggregate principal amount of its 6.250% Senior Notes due 2026 as additional notes (the "Additional Notes") under same indenture as Select's existing $550 million aggregate principal amount of 6.250% senior notes due 2026 that were originally issued on August 1, 2019 and, as such, will form a single series and trade interchangeably with such previously issued notes.

Selects intends to use a portion of the net proceeds of this offering, together with a portion of the net proceeds from a $615 million incremental term loan and, if required, available cash, to loan to its joint venture subsidiary, Concentra, Inc. ("Concentra"), pursuant to the terms of an intercompany loan agreement, an amount which will be used by Concentra to repay in full all currently outstanding term loan indebtedness under Concentra's first lien credit agreement. Any remaining net proceeds from the offering will be used by Select for general corporate purposes.

The notes and related guarantees were sold in a private placement, solely to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), or outside the United States to persons other than "U.S. persons" in compliance with Regulation S under the Securities Act. The notes and related guarantees have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

This notice does not constitute an offer to sell the notes, nor a solicitation for an offer to purchase the notes, in any jurisdiction in which such offer or solicitation would be unlawful. Any offer of the notes will be made only by means of a private offering memorandum. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

Investor inquiries:
Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
[email protected]

SOURCE Select Medical Holdings Corporation


These press releases may also interest you

at 06:47
Savanna Ingredients GmbH and Palmer Holland, Inc. have signed an exclusive distribution partnership for crystalline Allulose and Cellobiose in the USA and Canada markets....

at 06:45
As per a recent research report by Future Market Insights, Inc., a market...

at 06:45
Waterdrop Inc. ("Waterdrop", the "Company" or "we") , a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ended...

at 06:35
Merck , known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2024. "Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our...

at 06:35
Sage Therapeutics, Inc. , a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024. "The launch of ZURZUVAE is off to...

at 06:30
Sage Veterinary Imaging (SVI) has welcomed Peter Selover to its team as president and chief operating officer. Selover had previously served as chief executive officer of Exubrion Therapeutics....



News published on and distributed by: